Kyoto University iPS Cell Research

Translating iPS cell research to patient care

LocationJapan

Issue AreaEducation

Share
Share on Facebook Share on LinkedIn Share on Twitter Share to Buffer

Induced pluripotent stem cells (iPS cells) are one of key technology to realize the new era of medicine. They can differentiate into any type of cell in the body and proliferate indefinitely in culture. It will be useful in elucidating causes of disease and developing new drugs and therapies such as cell transplantation. To deliver the benefits of iPS cell research quickly, Kyoto University established the Center for iPS Cell Research and Application (CiRA) in Kyoto, Japan. The director of CiRA is Dr. Shinya Yamanaka, reported the establishment of iPS cells for the first time in the world and received the Nobel Prize for Physiology or Medicine in 2012. “iPS Cell Research Fund” supports CiRA researchers including Dr. Yamanaka. He shares: “Before my career as a scientist, I became a medical doctor. However, as a resident treating patients suffering from intractable diseases, I realized I could best help a large number of patients by conducting basic research to understand disease mechanisms and develop new therapies. Thanks to a great research team, this basic research led to iPS cells. iPS cells show great promise for regenerative medicine and drug discovery, especially for diseases that still have no effective treatment. To reach this promise, however, we need financial assistance to hire brilliant minds and create an excellent research environment. Your gift will go a long way to our ultimate goal of using iPS cells to bring better health to all around the world.”

About this Organization

LocationJapan
Issue AreaEducation

About Give2Asia

Give2Asia is a trusted partner for international philanthropy and the leader in donor-advised giving to the Asia-Pacific. Our mission is to strengthen communities in Asia by making cross-border giving easier and more effective. Since 2001, Give2Asia has facilitated more than $420 million of charitable grants across 20+ countries.